Part IThe Story
The Man in the Front Row
In December 1997, in an auditorium at the University of Pennsylvania, a former schoolteacher stood at a podium among university officials and announced that she and her husband would give $100 million to fight cancer. Madlyn Abramson had once taught in the Upper Darby School District and worked as a reading specialist in the Philadelphia public schools. Now she was a Penn trustee, and the pledge she announced was the second-largest gift in the university's history. Only Walter Annenberg's $120 million, in 1993, was bigger. It was one of the ten largest gifts made by anyone in the United States that year. The money would not arrive as a lump sum. It would be released on a project-by-project basis until all $100 million had been spent, which is roughly how a disciplined insurer pays out a claim: on presentation of evidence, one line item at a time.
Her husband sat in the front row. He said nothing.
That is nearly the whole record of Leonard Abramson's afternoon. He "kept a low profile and made no comments," the Chronicle of Philanthropy reported. Madlyn did the talking. She spoke about the breast cancer her doctors at Penn had diagnosed twelve years earlier, and about the care she believed she had received there. She spoke about John H. Glick, her oncologist for those twelve years, who would run the new institute. Asked whether her illness had shaped the gift, she gave a careful and honest answer: "I hope I would have done it anyway." Then, before the officials and the cameras, she addressed the man in the front row directly: "Leonard, you made this all possible."
She was right in more than one sense. The money came from the sale, about eighteen months earlier, of U.S. Healthcare, the health maintenance organization Abramson had built over two decades from a federally financed nonprofit in suburban Philadelphia into one of the largest managed-care companies in the country. Aetna had paid somewhere between $8.3 billion and $8.9 billion for it. The sources disagree, and a $600 million rounding error gives some sense of the scale. Abramson personally took home $967 million in cash and stock, plus a $25 million corporate jet and $10 million in consulting fees. Forbes that year ranked him No. 236 among the richest Americans and put his net worth at $760 million.
What had made it possible was a business that a large share of American doctors had come to resent and a growing share of American patients had come to fear. U.S. Healthcare's methods were simple to state. It paid physicians fixed fees, routed patients through primary-care gatekeepers, rewarded doctors who made fewer referrals to specialists, and paid new mothers cash to leave the hospital early. Under those methods it had spent, in its best year, 73 cents of every premium dollar on medical care. That was the lowest share in the industry, and Wall Street loved it. In the spring of 1996 the Philadelphia Inquirer ran two profiles of him on the same day. One was headlined "$1 Billion Man He's Collecting Huge Fares," a joke about the taxi he had once driven. The other was headlined, with almost legal restraint, "U.S. Healthcare's Abramson: Dedicated, Perhaps Ruthless."
So the man sitting silently in the front row of a cancer gift announcement was the man who had told hospitals that patients could go home sooner. He was paying, project by project, for the most expensive and least predictable kind of medicine: basic research, open-ended and slow, its returns measured in decades. Almost nothing on the public record suggests he found this contradictory. His wife held the microphone. His name went on the building.
By the Numbers
The Abramson Ledger
$2.5MFederal loan used to start HMO of Pennsylvania (some accounts say $3 million)
126,000Members when the HMO converted to for-profit status on December 20, 1982
2.2MPeople covered by U.S. Healthcare in 1995
73¢Share of each premium dollar spent on medical care in 1995, lowest in the industry
$8.3–8.9BPrice Aetna paid for U.S. Healthcare in 1996, depending on the source
$967MAbramson's personal windfall from the sale, in cash and stock
$140M+Abramson family giving to Penn Medicine, its largest donors
Son of Abram
The surname is a sentence: son of Abram. It is a patronymic, and like many Jewish patronymics in Central and Eastern Europe it began as a name assigned by the state. In the late eighteenth century Emperor Joseph II ordered the Jews of the Habsburg lands to take fixed, Germanic surnames so they could be counted and taxed. Jewish Currents, which keeps a day-by-day calendar of Jewish history, files the story of Jews acquiring family names under November 12.
Leonard Abramson was born on November 12, 1932.
His father, Joseph, had come to Philadelphia from Lithuania. He worked two jobs that sound, to modern ears, like they belong to two different men. He was a kosher butcher, and he was a cantor. During the week his work was the knife and the inspection: deciding what was fit, cutting away what was not, working under rules older than any government that had ever taxed his ancestors. On the Sabbath his work was the voice, singing a congregation's prayers on its behalf. Leonard's mother, Zipporah, née Sebotnick, ran the home. Leonard was their only child.
He grew up in Strawberry Mansion, a North Philadelphia neighborhood along the edge of Fairmount Park. The New York Times, in its 1996 account of the Aetna deal, placed his childhood in West Philadelphia. His daughters and the obituaries say Strawberry Mansion, and so will we. What his daughters said most clearly, after his death, was that he rarely talked about those years. "It was not a happy one," the Jewish Exponent paraphrased them. "He was extremely poor," his daughter Judy Felgoise said, "and he worked very hard to succeed." In a 1991 interview with Forbes he explained what the hard work was for. He had wanted to be a better businessman than his father. "I felt I had to be successful."
That is the whole of his own account, as far as the record goes. He never wrote a memoir, and his one book is about health-care policy. There is no confessional Esquire profile. The man Aetna's spokespeople would later describe as someone who "never talks to the media" had, apparently, made an early decision about how much of himself to show, and kept it.
Madlyn Kornberg came from a different Philadelphia. She was born in the city and graduated from the Philadelphia High School for Girls, the selective public school that has sent generations of the city's ambitious daughters onward. She took bachelor's and master's degrees in education at Penn, in 1957 and 1960. Her father, Maurice H. Kornberg, was a dentist and an alumnus of Temple's dental school, a professional man in the solid sense. She married Leonard in August 1957, while she was still at the start of a teaching career she would later describe to her daughter as "a career that she enjoyed when she was young." According to their daughters, her teacher's salary helped pay for his schooling after they married. The cantor's son married the dentist's daughter, and the teacher underwrote the pharmacist.
Fifty-six years later, in 2013, the couple gave $10 million to Temple University's dental school for student scholarships. In return the school took the name of Maurice H. Kornberg. "Leonard knew my father well, and both loved and respected him," Madlyn told the Jewish Exponent. "My husband intended this gift as a wonderful present to me to honor the memory of this very special man."
Wealthy sons of Jewish immigrants have a recognizable habit of turning money into a monument to a father. Leslie Wexner, five years younger than Abramson, was the son of a Russian-born clothing merchant whose small Columbus store was named Leslie's, after the boy. Wexner later pledged $25 million toward a $43 million arts center at Ohio State and named it for his father, Harry. Abramson's name, his wife's name, and his father-in-law's name are spread across Philadelphia: on a cancer center, a pediatric research building, a dental school, a center for Jewish elder care. I could not find a building anywhere named for Joseph Abramson, the butcher and cantor from Lithuania. That may mean nothing. It may also be the most honest thing the record tells us about that unhappy childhood.
The Meter and the Flat Fee
He paid for pharmacy school by driving a cab.
The detail turns up in nearly every account of his life, and for good reason. It is the kind of origin story American business journalism loves: the hack license, the late shifts, the young man doing chemistry problems between fares. The headline writers never tired of it. "Collecting Huge Fares." "The biggest tip in his life." "Sure is better than driving a cab," as Forbes wrote in 1999.
The cab also offers a quieter lesson, one the headline writers had no reason to draw. A taxi runs on a meter, and the meter does not care whether the trip was necessary. Every block adds to the fare. A detour pays better than a straight line, and a long ride pays better than a short one. The incentive is built into the machine. Nobody has to be dishonest for the meter to reward the long way around. Whether the young Abramson thought about any of this behind the wheel, no source says. But the business he spent his life building rested on the claim that American medicine had been running on a meter: fee-for-service, à la carte, every admission and test and extra hospital day another click of the dial. His answer was to replace the meter with a flat fare paid in advance, and then to own the route.
He did not get there directly. He graduated from the Philadelphia College of Pharmacy and Science, later the University of the Sciences, and later took a master's degree in public administration from Penn State. The pharmacy degree and the public-administration degree, taken together, describe the two halves of the business he would eventually build. He went to work selling drugs for Parke-Davis, the Detroit pharmaceutical house. He spent six years as a retail pharmacist behind a counter, filling prescriptions written by doctors whose billing he could not see. Corporate histories say he started two small businesses along the way. They do not record what those businesses were, and no source describes them as successful. Then he took a job at R.H. Medical Inc., a small hospital-management company in Cheltenham, just over the city line, as vice president for corporate development.
His daughter Judy is unsentimental about this period. He did not love pharmacy, she said. "I think he just needed a career. He was sort of guided that this was a good way to start a career. He pivoted so many times after that."
He pivoted so many times. For a man who would become a byword for a single, relentlessly executed idea, the first two decades of his working life look like drift: salesman, pharmacist, small-business owner, hospital-management executive. But it was the kind of drift that builds an education. By the time he was in his early forties he had seen the American health system from the drug company's sales territory, from the pharmacist's counter, from the small owner's ledger, and from the hospital administrator's office. He had seen every part of it except the doctor's office, which may explain why he never fully trusted it.
A Forbes list from 1999 profiles the people who had made fortunes in American medicine. Two entries above Abramson sits William Cook of Bloomington, Indiana, worth $1.1 billion from catheters and medical supplies. Cook was a Northwestern graduate who "made living as cabbie in the 1950s," then worked as a medical-supplies salesman and quit in 1963 to start his own company. Two cab drivers on the same list, two drug-and-supply salesmen who left to build something of their own. American medicine in the 1950s apparently looked best, to a certain kind of ambitious young man, from the driver's seat.
A Law Is a Business Plan
In 1973 Congress passed the Health Maintenance Organization Act. Most Americans paid no attention. Leonard Abramson paid close attention.
The law did two things that mattered to him. It made federal money available to start HMOs, which were then a mostly experimental model in which a single organization took a fixed, prepaid fee to provide all of a member's care. And it required large employers to offer their workers an HMO option alongside conventional insurance, provided a qualified HMO in the area wanted to be offered. It also specified that employer payments to HMOs could be no lower than payments to insurers.
Read as a merchant would read it, the statute did more than enable a new kind of company. It supplied the financing, guaranteed the sales channel, and set a floor under the price. The federal government had written a business plan and left the founder's name blank.
He filled it in. With federal loans, $2.5 million by the corporate histories' account and $3 million by others, he left R.H. Medical and started a nonprofit called the Health Maintenance Organization of Pennsylvania. Most accounts date the founding to 1975. In 1976 the Commonwealth of Pennsylvania licensed it. In June 1977 it qualified for federal certification, which opened the employer-mandate doors. It was then a nonprofit, community-based plan with fewer than 20,000 members. Its eventual home, 980 Jolly Road in Blue Bell, Montgomery County, was the kind of address that suggests an office park rather than a revolution.
The first important decision was architectural, and it went against the efficiency logic the rest of his career would be known for.
The classic HMO was the staff model. The plan employed the doctors and put them in its own clinic buildings, and patients went to the clinic. It was efficient and integrated, and it could be institutional and impersonal. Abramson chose instead the individual practice association. HMO-PA contracted with independent physicians who kept their own offices, and members chose their doctor from an approved list. The patient got a family doctor in a familiar office rather than a clinic waiting room. The corporate histories note that the arrangement was usually less cost-effective than the staff model. Abramson accepted that cost on purpose and then spent years finding ways to win the efficiency back.
— Larry Levitt, executive vice president for health policy, KFF, 2026Until then, HMOs were very closed systems and U.S. Healthcare was one of the first companies to pioneer a much more open-ended HMO that could be expanded rapidly. It was also one of the first HMOs to convert from nonprofit to for profit, and many others followed in its footsteps.
Levitt's two sentences contain most of the business history of American managed care. The open network meant he could grow without building clinics. Every new county needed contracts, not concrete, so expansion was a sales problem rather than a construction problem. The for-profit conversion, which was still years away, meant the growth could eventually be financed by the public markets rather than the federal government. A man who had spent six years selling Parke-Davis products to doctors understood something the closed-model idealists did not. The doctor's office was where trust lived. You did not take the doctor's office away from people. You moved into it.
Paying Mothers to Go Home
The IPA model gave the patient a familiar doctor. Abramson then set about changing that doctor's incentives.
Two mechanisms recur in every account of the early company. One was aimed at physicians, the other at patients, and together they show his theory of human behavior more clearly than anything he wrote. Doctors in the network received financial incentives for making fewer expensive referrals to specialists. The primary-care physician became a gatekeeper, paid in a way that made each referral a cost to be justified rather than a convenience to be granted. And new mothers received cash bonuses for going home early from the hospital after giving birth.
The second of these is the one people remember, and it was meant to be. A fee-for-service hospital earned more from every additional day a mother stayed in a bed. An HMO paid for that bed and earned nothing from it. Abramson took some of the money the bed would have cost and offered part of it to the mother. He was not prohibiting the long stay. He was paying people not to choose it, which is a very different approach and a much more American one.
"When we started, the average maternity stay in a hospital was four days," he told the New York Times in 1995. "Now it is 24 hours and studies show that babies are healthier, moms are healthier. The longer length of stay did not give better quality care."
There is a version of Abramson that the people who worked for him still defend, and it is not a cynical one. U.S. Healthcare, his obituaries note, promoted childhood immunizations and mammograms for older women before either was standard. It pushed reduced fees to specialists and shorter hospital stays. It "championed strict standards and accountability for medical professionals," in the Inquirer's words, and its founder criticized people who exploited a system "then rife with loopholes." In this account, prevention was the product, and cost savings followed from better medicine rather than from refusing care.
David Snow is the best witness for this version. His father was an internist. Snow took a master's in health administration at Duke and then spent a 43-year career running large parts of the American health-insurance business: U.S. Healthcare, then AmeriChoice, Oxford Health Plans, Empire Blue Cross and Blue Shield, Medco, and Cedar Gate Technologies. Asked in 2022 to name his favorite healthcare revolutionary, he named his first boss before anyone else. "Leonard was a passionate agent for change," Snow said, "implementing primary-care attribution models, primary-care gatekeeper models, capitated delivery systems. Even back then, Leonard was pushing to change the fee-for-service paradigm and eliminate the perverse incentives. He was evangelical about it."
Evangelical is an interesting word to use about a cantor's son.
The other version is also on the record. David Ansel was a pediatrician in North Andover, Massachusetts, a small-town doctor who apparently decided the problem was worth complaining about publicly. He told the Baltimore Sun in 1994 that U.S. Healthcare, by paying him a fixed fee per patient regardless of how sick the patient was, was refusing to acknowledge how much more time the sickest children required. The company, he said, "pressured him to refer patients to inappropriate specialists and hospitals." U.S. Healthcare declined to comment. The Times, in Abramson's obituary, summarized the criticism with a newspaper's fairness: "some doctors and consumer advocates said that the company sometimes shortchanged services provided to patients, including time they needed to recover in hospitals."
Both versions are true, and they are true about the same mechanism. A flat fee per patient rewards a doctor for keeping a healthy patient healthy, which is the point of prevention. The same flat fee penalizes the doctor for taking on a patient who is sick and will stay sick. Abramson had taken the meter out of the cab. A flat fare encourages its own kind of driving.
Seventy-Three Cents
On December 20, 1982, HMO of Pennsylvania stopped being a nonprofit. Some accounts put the decision in 1981 and the legal conversion at the end of 1982. The company became a profit-making corporation called United States Health Care Systems, Inc. It had more than 126,000 members, and the corporate histories call it the fastest-growing HMO in the country. In 1983 the parent company, now called U.S. Healthcare Inc., went public.
That sequence is the hinge of his career, and it deserves to be stated plainly. A company started with federal loans, under a federal statute designed to encourage a new form of health care, built its membership as a community nonprofit for seven years and then converted that membership into equity owned by its founder and, after 1983, by public shareholders. It was legal and it was quick. And, as Levitt said, many others followed in its footsteps. Whether that was a betrayal of the 1973 Act's intentions or the fulfillment of them depends on what you think Congress wanted. At least one man in Blue Bell was clear about his own view.
By the early 1990s, according to one corporate history, U.S. Healthcare had 2,300 employees, $1.7 billion in sales, and more than 1.3 million members in eight northeastern states. By 1995 it covered some 2.2 million people. That year it spent about 73 cents of each premium dollar on medical costs, the lowest proportion in the industry.
That number, the medical loss ratio, was the hidden center of everything. A securities complaint filed against the company in 1995 defined it clearly. The MLR is the ratio of medical expenses paid out to the premium income taken in. A low MLR means high margins and strong profitability. Each penny of difference between U.S. Healthcare's ratio and a competitor's was, at the company's scale, tens of millions of dollars.
Abramson knew exactly how much each penny was worth, and he said so in 1990.
— Leonard Abramson, to the Philadelphia Inquirer, 1990If you're 98 percent right in this business, it's not good enough. Two percent off costs me $20 million.
The same year, the Inquirer business writer Peter Binzen described him as a "low-profile, soft-spoken executive who rarely raised his voice in public." The combination tells you a lot: a quiet man who was clear about the arithmetic. He was routinely among the highest-paid chief executives in the Philadelphia region. In 1991 the Inquirer ran a long investigation by Gilbert M. Gaul under a headline that could fit on a pharmacy label: "U.S. Healthcare Has Found a Prescription for Profits."
He answered his critics the way quiet men often do, in print. In 1990 Grove Press published Healing Our Health Care System, under his name. It called the American health system "nothing less than a national disgrace," a phrase that sounded strange coming from one of the people who had profited most from it. The book's argument was that the system's inefficiency, cost, impersonality, and dependence on technology were the fault of mismanagement and greed among the industry's major players. The cure was competition: reform shared between government and business, carried out in a competitive market, and carefully monitored. The model he proposed, with no apparent embarrassment, was his own HMO.
— Leonard Abramson, Healing Our Health Care System, 1990By applying American capitalism to health care, I have realized the American dream.
The reviewers were polite and pointed. Publishers Weekly called the book "astute, succinct, occasionally self-serving." Library Journal said it was not suitable for professional or graduate collections and steered serious readers toward Eli Ginzberg's The Medical Triangle. The book did its real work in places where reviews did not count: in employer benefits offices, at industry conferences, in the minds of the buyers and analysts who decided which HMO to choose and which stock to own. "If industry leaders know there are solutions, they're going to call for them," he told the Inquirer. "Innovation leads to emulation." First-edition hardcovers now sell online for $3.50 with free shipping.
There were lawsuits, as there would be for any company whose profits came from deciding what not to pay for. In 1993, in Greenfield v. U.S. Healthcare, the company and Abramson personally asked Chief Judge Donald Bechtle of the Eastern District of Pennsylvania to sanction the plaintiffs' lawyers. That is not the posture of a defendant who expects to settle quietly. In 1995 a real-estate company filed a class action, J/H Real Estate Inc. v. Abramson, on behalf of shareholders who had bought U.S. Healthcare stock between October 5, 1994, and April 19, 1995. It accused Abramson and his top executive Costas C. Nicolaides of presenting the company's prospects in a consistently positive light while holding materially adverse information. That year the Federal Trade Commission sent a closing letter addressed to "Leonard Abramson, President, U.S. Healthcare, Inc." Such a letter marks the end of an inquiry. It was the sort of correspondence any large company in a consolidating industry eventually collects.
None of this slowed him down. The legal record mostly confirms that U.S. Healthcare's margin had become a matter of public importance: something shareholders sued over, regulators looked at, and doctors resented. The 73 cents made him rich. It also made him a target.
The Biggest Tip
In the spring of 1996 he went to New York to sell the company.
The press conference was held at the Waldorf-Astoria. The Times noted that the 63-year-old founder appeared "trim and deeply tanned," which was its way of saying he looked like a man who wintered in Jupiter, Florida, and did. Aetna Life & Casualty, the old Hartford insurer, was acquiring U.S. Healthcare. Abramson would come away with about $492 million in cash, the biggest cash payout in the deal, and would also become Aetna's largest single shareholder and a member of its board. The Times headline was "Once a Pharmacist, Now a Deal Maker." The article opened by calling Abramson "a one-time cab driver" who "walked away yesterday with the biggest tip in his life."
The price, like his birthplace, depends on the source. Forbes and the encyclopedias say $8.3 billion. The Inquirer, the Los Angeles Times, and the Chronicle of Philanthropy say $8.9 billion. The Times settled on "more than $8 billion." The total package Abramson received was $967 million in cash and stock, a $25 million corporate jet, and $10 million in consulting fees.
His public explanation for selling was a lesson in industry structure, not a statement about a payday. The deal, he told the Times, was necessary "to get the mass we needed, the power to negotiate with the physicians, the hospitals, the drug companies" and to force down their charges. This was the IPA model's logic followed to its end. If your business consists of contracts with independent providers, your strength is your size relative to them. U.S. Healthcare, with 2.2 million lives in the Northeast, could squeeze a community hospital. Aetna U.S. Healthcare could squeeze a health system. He was selling the company in order to make its central idea stronger.
There is one more story about the sale, and it comes from his daughters, told after his death to the Jewish Exponent. At some point in the negotiations Abramson called the deal off. He believed Aetna intended to lay off too many of his people. Judy Felgoise remembered his words: "I will not allow you to come in and destroy this and fire all these people."
Her account is secondhand and was offered as part of a eulogy, and it should be weighed as such. It also fits everything else his employees have said. Decades after the sale, his daughters said, former U.S. Healthcare workers still post about him in a private Facebook group, where he is remembered as "Mr. A." "I never worked for a better man," one former colleague wrote in a tribute. Another said he "encouraged a commitment to customer service that stayed with me throughout my career." The man whom doctors and consumer advocates accused of rationing care treated the people on his payroll with a protectiveness that his daughters describe as total. Both accounts can be true at once.
The rest of the world reached its own conclusions. In July 1998 The Lancet published an essay by the physicians David Himmelstein and Steffie Woolhandler, sharp critics of American market medicine, that listed the failures of the managed-care era. Among them: "Hospital chains' profits reach $100 per patient per day, and one HMO entrepreneur has netted $990 million in a takeover deal." The essay named no one. Readers in Philadelphia could work out who was meant.
In the late 1990s the syndicated television program Inside Edition, preparing an exposé on how wealthy HMO executives lived, sent a crew to Jupiter and secretly videotaped Abramson and his family at their home. He sued the show for invasion of privacy. The man who would not talk to reporters had been filmed without his consent, and he responded the way he responded to most threats, with lawyers.
Too Busy
The board seat lasted four years.
From 1996 to 2000 Abramson was a director of Aetna, the company that had bought his. He was also, at the same time, a paid consultant to it, receiving $3 million a year under the terms of the sale. According to Aetna's filings with the Securities and Exchange Commission, his two daughters and a son-in-law were paid millions of dollars for doing business with the insurer. In 1999 Forbes noted, with its usual brevity, that Abramson had "dumped most of his shares, but ties remain: multimillion-dollar consulting contract, private plane maintained by Aetna." It valued him at $875 million and added: "Sure is better than driving a cab, which paid for studies."
The arrangement was legal. It was disclosed. It also directly contradicted the corporate-governance thinking that was taking hold by the late 1990s, which held that a director should be independent of the company he oversees. Some shareholders and governance experts said so publicly. Aetna rejected the conflict-of-interest charge and pointed out that the Abramson payments had been negotiated as part of the acquisition and disclosed to shareholders.
On a Tuesday in June 2000, Abramson released a statement saying he was resigning from Aetna's board because he was too busy to continue. He did not return reporters' calls. Aetna's spokespeople explained, almost apologetically, that he never talked to the media. The Inquirer reported that his departure was seen as part of a housecleaning at the troubled insurer. The Los Angeles Times ran the Associated Press story. The last line noted that Aetna shares had fallen 63 cents that day, to $67.50 on the New York Stock Exchange.
The episode is a small one, and it is easy to skip in an account of a man who gave away more than $140 million. It is worth including anyway, because it shows the same pattern as everything else. He had negotiated the sale the way he negotiated a provider contract, protecting everything his side could protect, his family included. He had kept the plane, the consulting fees, and the seat. When the protections became a liability, he left in a three-sentence statement and said nothing more. Harvard Business School would later list him among its Great American Business Leaders of the Twentieth Century, crediting him with having "accurately predicted the need for prepaid medical plans to manage spiraling medical spending." After leaving Aetna he set up the Abramson Group and consulted for Aetna and other companies.
He was 67, and he was too busy, as he had said. He was giving money away on a large scale.
When Bad Things Happen to the Right People
The cancer had been found in the mid-1980s, a dozen years before the gift. Madlyn was treated at Penn, at a cancer center much smaller than the one that would later carry her name. Her doctor was John H. Glick. He was a longtime member of Penn's faculty, and he stayed her oncologist for twelve years. When the couple decided what to do with the Aetna money, they put Glick in charge of the institute it would create. His name is now attached to an endowed chair at the cancer center, the John H. Glick, MD Abramson Cancer Center Director's Professorship. The doctor and the patients built the institution together and are named in it together.
— Madlyn Abramson, at the announcement of the $100 million gift to the University of Pennsylvania, 1997I guess there is a theory that when bad things happen to the right people, good things happen from it.
The gift's structure is the most revealing thing about it. The $100 million would be released project by project, by the family's own Abramson Family Foundation, established in 1996, the year of the sale. That is how an underwriter gives. Penn said the money would go first to the cancers that killed the most Americans: lung, gastrointestinal, breast, prostate, and ovarian. The man who had built a fortune on the idea that a dollar should go where the outcome was greatest had chosen his diseases by the same logic. Madlyn put it in a patient's language: "Having been a cancer patient, I understand the importance of a patient-centered approach in all research and clinical activities. High-quality, personalized care will be the ultimate goal of all our efforts."
Personalized care. Twenty years earlier the selling point of HMO-PA had been personal care given by doctors in their own offices, the patient's own physician instead of a clinic. The language had come full circle.
What the money bought is unusually well documented, because Penn had every reason to document it. In 2002 the university renamed its cancer center the Abramson Cancer Center. In May 2010 the couple added $25.5 million, bringing their total support of Penn Medicine to $125 million and making them its largest donors. In the twelve years since the institute's founding, Penn reported, the Abramson money had recruited twenty scientists to the faculty and started research programs in cancer cell metabolism, cancer vaccines, and cell-based immunotherapy, along with work on the DNA repair systems involved in breast cancer and lymphoma. Penn's medical leadership later described the Abramsons as "early pioneers in funding basic science and cancer immunotherapy." At the 2010 Dean's Dinner, during Alumni Weekend, the couple received the first two dean's medals the medical school ever awarded. By 2020 their giving to Penn passed $140 million, which also endowed the Madlyn and Leonard Abramson Professorship in Clinical Oncology and professorships in sarcoma care and anesthesiology.
Cell-based immunotherapy was, in the late 1990s and 2000s, exactly the kind of open-ended, high-risk, uncertain-payoff research that no managed-care company would ever have reimbursed. Abramson spent his business career making sure that every medical dollar could be justified by an outcome. He spent his philanthropic career paying for the work that would, years later, produce outcomes no one could have priced in advance.
He was not giving only to Penn. In 1995, before the sale, the couple gave $15 million for a pediatric research center at Children's Hospital of Philadelphia. The Leonard and Madlyn Abramson Pediatric Research Center became the hospital's first research building, and about 700 CHOP employees now go to work there every day. The family later supported CHOP's pediatric emergency department. In Horsham, Montgomery County, they founded the Madlyn and Leonard Abramson Center for Jewish Life, an assisted-living, skilled-nursing, and gerontological-research campus. Its first resident moved in in October 2001, and a hospice program added in 2008 was later opened to the wider community. At Johns Hopkins, where Leonard became a trustee emeritus, they endowed a professorship in neurodegenerative diseases. In 2002 he joined Edgar Bronfman, Lynn Schusterman, Michael Steinhardt, and Ron Lauder in covering a $300,000 program to prepare Jewish students for the campus fights over Israel. He gave to the Foundation for Defense of Democracies, a hawkish Washington think tank.
Asked whether Jewish tradition had shaped her giving, Madlyn reached for the Hebrew word that means both righteousness and charity. "Jewish people are taught the word tzedakah . . . from the time they are children," she said. "We are very Jewish-minded and American-minded."
The two hyphenated adjectives, side by side, are the closest anyone in the family came to a summary of his life. The cantor's son had applied American capitalism to health care, by his own account, and realized the American dream. Then he gave the proceeds away under rules much older than the dream.
"All philanthropic projects were a joint thing they'd done together," Nancy Wolfson said. In public, though, only one of them ever spoke.
What Grows in Blue Bell
Madlyn Abramson died on April 15, 2020, of complications from a stroke, at the couple's home in Blue Bell. She was 84. She died in the first weeks of the pandemic, when hospitals across the country were rationing beds for reasons no insurer had planned for. "It was a true love story," their daughter Nancy said.
Leonard lived six more years.
He did not retire. After the Aetna sale he had consulted and served on boards, and in his last years he kept going to the family office. In 2019 he sat down for eleven minutes with Madeline Bell, CEO of Children's Hospital of Philadelphia, for her podcast, to talk about thirty years of his family's support for the hospital. The episode was released on July 3. In August 2022 he sold the waterfront house at Admirals Cove in Jupiter, 7,509 square feet, for a reported $7 million, which was the house Inside Edition had once filmed without asking. He spent summers in Maine.
He told his family that three qualities mattered, honesty, integrity, and loyalty, and his daughters say he repeated them "all the time." His daughter Nancy joined the Penn Medicine board. There were eleven grandchildren and two great-grandchildren. He took up things that had nothing to do with medical loss ratios. He painted. He played the piano. He gardened. He went boating.
He kept going to the office until the Friday before he died, his daughter Judy said. That was July 3, 2026. The next day, a Saturday and the Fourth of July, he died at home in Blue Bell of age-associated decline. He was 93. The same suburb had once been home to 980 Jolly Road, the address of the company that the Health Maintenance Organization Act of 1973 had made possible and that he had made his own.
Among the other things he did with his hands in those late years, he kept bonsai trees.
A bonsai is not a small tree. It is a full-sized tree that someone, every season, with a small pair of shears, has decided against.
Part IIThe Playbook
What follows is drawn from the record of a builder who rarely explained himself, so the principles are inferred from what he did rather than from what he said. Abramson left one book, a handful of quotations, and a long trail of decisions. Those decisions repay close study by anyone building in a regulated industry, anyone whose margin depends on changing other people's incentives, and anyone who expects to face, one day, the question of what to do with the proceeds. Some of these lessons are worth copying. A few are worth learning as warnings. Most are both.
The principles
- 1.Read the statute as a business plan.
- 2.Borrow the public's balance sheet, then change your form.
- 3.Pay for the experience the customer will tolerate, then win back the efficiency.
- 4.Price the behavior, not the service.
- 5.Know exactly what one percent is worth.
- 6.Write the indictment of your own industry.
- 7.Sell when scale becomes the product.
- 8.Spend your exit leverage on your people.
- 9.Silence is a strategy, and it has a cost.
- 10.Design the tail of the deal for the next decade's norms.
- 11.Give the way you underwrote.
- 12.Let the person who earned the story tell it.
Principle 1
Read the statute as a business plan
The Health Maintenance Organization Act of 1973 was written as policy, and Abramson read it as a term sheet. It offered startup capital through federal loans, a guaranteed sales channel through the requirement that large employers offer an HMO option, and protected pricing through the rule that HMO payments be no lower than insurers'. Most people in health care saw an experiment. He saw capital, distribution, and pricing supplied by the government, and he founded his company within two years of the law's passage.
The general lesson is that regulation often contains the most valuable business plans available. They hide in the plain text of laws that most operators skim for compliance risk and never read for opportunity. An incumbent reads a new statute and asks what it now has to do. Abramson read it and asked what it now made possible.
A
From Statute to Sale
How a federal law became a company, and a company became a fortune.
1973
Congress passes the HMO Act, which mandates that employers offer an HMO option and provides federal startup funding.
1975
Abramson founds HMO of Pennsylvania with $2.5–3 million in federal loans.
1976
Pennsylvania licenses HMO-PA.
1977
Federal certification in June; fewer than 20,000 members.
1982
Converts to for-profit on December 20 with 126,000 members.
1983
U.S. Healthcare goes public.
1990
Publishes Healing Our Health Care System.
1995
Covers 2.2 million people at a 73-cent medical loss ratio.
1996
Sells to Aetna for $8.3–8.9 billion; personal windfall of $967 million.
2000
Resigns from Aetna's board amid conflict-of-interest criticism.
Tactic: For any regulation touching your industry, write a one-page memo answering only one question: what does this law pay for, mandate buying, or protect, and who is not yet positioned to collect?
Principle 2
Borrow the public's balance sheet, then change your form
HMO-PA was born a nonprofit, funded with federal money, during the years when building membership was slow and uncertain. Once the model was proven at 126,000 members, the fastest growth of any HMO in the country, it became a for-profit company. One year later it was public. The nonprofit form absorbed the risk of the early years, and the for-profit form captured the value later. Levitt notes that "many others followed in its footsteps," which is the strongest evidence that the sequence was a strategy rather than an accident.
The playbook is clear and so is the controversy, and serious operators should weigh both. The nonprofit-to-for-profit conversion can be a legitimate way to match corporate form to stage. It can also look, to critics, like the privatization of a public investment. Abramson accepted that reputational cost, and it followed him to The Lancet.
Tactic: If your early capital comes with public-interest strings, decide in advance the milestones at which you would change your structure, and be ready to defend the conversion publicly as a fair exchange rather than a quiet exit.
Principle 3
Pay for the experience the customer will tolerate, then win back the efficiency
The staff-model HMO was cheaper. Abramson chose the IPA model anyway, because the staff model's clinic waiting room was something many patients and employers would not accept. Letting members keep a doctor in a private office cost him efficiency up front. He then spent the following years recovering that efficiency through incentives, gatekeeping, and contracting, without ever giving up the experience that made the product sellable.
⚕
Two Models of the HMO
Abramson chose the less efficient design and made it the faster-growing one.
| Dimension | Staff-model HMO | Abramson's IPA model |
|---|---|---|
| Where care happens | Plan-owned clinic buildings | Physicians' own private offices |
| Patient choice | Assigned to the plan's staff | Choose from a list of approved doctors |
| Cost efficiency | Higher, through tight integration | Lower by design, recovered through incentives |
| Expansion constraint | Capital: build clinics | Sales: sign contracts |
| Customer perception | Institutional, impersonal | "My doctor" |
The deeper advantage was speed. A network built from contracts grows as fast as a sales force can sign doctors, and a network built from buildings grows as fast as construction allows. The design he chose to keep customers happy also turned out to be the design that let him grow quickly.
Tactic: Identify the most efficient version of your product that customers would refuse, ship the version they will accept, and make the efficiency gap a standing engineering problem rather than a reason to compromise the experience.
Principle 4
Price the behavior, not the service
The cash bonus for new mothers who went home early is the clearest single example of how Abramson thought. He did not forbid the four-day maternity stay. He offered the patient part of the money the stay would have cost, and the average stay fell from four days to 24 hours. The incentives for physicians who made fewer referrals worked the same way: no prohibition, just a change in what was profitable. He had grown up surrounded by a fee-for-service system that rewarded every additional unit of care. He replaced it with a system that rewarded every unit avoided.
The warning is built into the success. Pediatricians like David Ansel argued that per-patient flat fees penalized doctors for caring for the sickest patients. An incentive powerful enough to change behavior is powerful enough to change the wrong behavior. Abramson's defenders point to immunizations and mammograms. His critics point to sick patients who were turned away. Both sides are describing the same mechanism.
Tactic: Before deploying any incentive, write down the specific bad behavior it could reward at the edges, decide how you will measure that behavior, and commit to the measurement before you see the margin improvement.
Principle 5
Know exactly what one percent is worth
"If you're 98 percent right in this business, it's not good enough. Two percent off costs me $20 million." By 1990 Abramson had turned his company's economics into a single number that he understood to the dollar: the medical loss ratio, which reached 73 cents per premium dollar in 1995, the lowest in the industry. Everyone in the company could understand the stakes because the founder had already done the arithmetic.
The weakness of building on a single number is that everyone else learns to watch it too. Shareholders in J/H Real Estate v. Abramson argued that the company's portrayal of its prospects had inflated the stock, and the complaint was organized around the MLR. A number that tells investors you are excellent can be turned against you, in court, the moment it moves.
Tactic: Identify the one ratio that most determines your economics, calculate the dollar value of a single percentage point at your current scale, and make sure every manager can recite it.
Principle 6
Write the indictment of your own industry
In 1990 the founder of one of the most profitable HMOs in America published a book calling American health care "nothing less than a national disgrace." This was not self-criticism. It was positioning. By describing the industry's failings (mismanagement, greed, inefficiency, impersonality) as the very problems his model claimed to solve, Abramson put himself on the reform side of a debate in which he was also among the largest beneficiaries. "Innovation leads to emulation," he said, which was another way of saying that he wanted to set the standard everyone else would be measured against.
The reviewers spotted the self-interest immediately, and called the book "occasionally self-serving." That turned out not to matter. The book's audience was not health-policy scholars. It was the employers, analysts, and executives who would decide which model to buy.
Tactic: Write the clearest diagnosis of your industry's dysfunction that you can honestly sign, and make sure your own product is the logical treatment.
Principle 7
Sell when scale becomes the product
Abramson's explanation for selling to Aetna was not about cashing out. It was about bargaining power. The deal was necessary, he said, "to get the mass we needed, the power to negotiate with the physicians, the hospitals, the drug companies." For a company whose entire model was contracting with independent providers, the decisive competitive variable had become size relative to those providers. When a business's main advantage is its leverage over suppliers and its own size has stopped growing that leverage, the founder's job changes from building to combining.
The timing was striking. He sold in 1996, during a wave of consolidation, at or near the peak of managed care's reputation with investors and before the patient backlash of the late 1990s hardened. Whether that was foresight or luck, the record does not say.
Tactic: Ask each year whether your primary competitive advantage is still growing with your own efforts, or whether it now depends mainly on combined size you cannot reach alone. If the answer is the latter, start the conversation before your competitors do.
Principle 8
Spend your exit leverage on your people
According to his daughters, Abramson at one point called off the Aetna deal because he believed too many U.S. Healthcare employees would be fired. "I will not allow you to come in and destroy this and fire all these people." Whatever the precise terms of the final agreement, the reported loyalty left a lasting result. Thirty years after the sale, former employees still gather in a Facebook group to remember "Mr. A," and one wrote after his death, "I never worked for a better man."
A founder has the most leverage over a buyer in the period between the term sheet and the close, when the buyer has committed reputationally but has not yet won. Most founders spend that leverage on price. Abramson, at least once, spent it on headcount. The reputational return was lasting goodwill from the people who knew him best, and that goodwill partly offset the hostility of doctors and critics who knew him only through his company's policies.
Tactic: Before negotiating the sale of your company, decide in writing which employee protections you would walk away over, so that you treat them as non-negotiable rather than as items to trade away late in the process.
Principle 9
Silence is a strategy, and it has a cost
"Aetna officials say Abramson … never talks to the media." He was soft-spoken and rarely raised his voice in public, and at his own $100 million gift announcement he made no comments. His silence protected him from misquotation and from the exposure that comes with being a public figure. It also meant that other people told his story. The Inquirer called him "Dedicated, Perhaps Ruthless." The Lancet referred to him without using his name. Inside Edition filmed his family without permission.
§
The Two Records
How Abramson's methods were described by supporters and critics, often about the same practice.
| Practice | As defended | As criticized |
|---|---|---|
| Prevention Maternity incentives | Stays fell from four days to 24 hours; "babies are healthier, moms are healthier" | Patients pushed out before they had recovered |
| Incentive Fixed per-patient fees | Ended the perverse incentives of fee-for-service | Penalized doctors for treating the sickest patients |
| Margin 73¢ medical loss ratio | Proof of efficiency; celebrated by Wall Street | Evidence of services withheld |
| Governance Post-sale consulting | Negotiated and disclosed as part of the deal | Conflict of interest for a sitting director |
The lesson is not that founders should seek publicity. It is that refusing to explain yourself is a choice with consequences, and those consequences are hardest to bear in businesses whose decisions affect people's bodies. A company that decides what medical care gets paid for will be judged by its denials unless someone makes the case for its reasoning in public.
Tactic: If you choose to stay quiet, designate one credible person to explain the company's tradeoffs regularly and on the record, so that your silence does not leave the story to your critics.
Principle 10
Design the tail of the deal for the next decade's norms
The terms that followed Abramson out of the sale, $3 million a year in consulting, business for his daughters and son-in-law, a private plane maintained by Aetna, and a board seat, were negotiated under one set of governance norms. They ended under another. By 2000, director independence had become a matter of shareholder activism, and Abramson resigned in a three-sentence statement saying he was "too busy." Aetna's shares fell 63 cents that day. The arrangements had been legal and disclosed. They had also been designed for the expectations of the time they were signed rather than the time they would run.
Founders who negotiate earnouts, consulting agreements, and board roles should assume that the governance standards of the deal's final year will be stricter than those of its first. Terms that look like reasonable compensation at signing can look like self-dealing four years later.
Tactic: Test every post-close arrangement against the strictest governance standard you can imagine applying five years from now, and drop anything that would fail it.
Principle 11
Give the way you underwrote
The $100 million gift to Penn was paid on a project-by-project basis until it was spent. It focused first on the cancers that killed the most Americans. It recruited twenty scientists and funded cell-based immunotherapy and cancer vaccines before either was fashionable. Abramson's philanthropy was disciplined in the same way his company had been: money released against defined projects, aimed where the burden was greatest, and measured by results that Penn could report in detail twelve years later.
What changed was his tolerance for uncertainty. In business, he paid only for what could be justified. In philanthropy, he funded basic science, the least predictable investment in medicine. He kept the discipline and dropped the demand for a guaranteed return. That may be the best model his career offers: rigor in the structure of a gift, combined with patience about its results.
Tactic: Structure major gifts as staged commitments tied to defined projects, and aim them at the high-risk work that no reimbursement system or commercial investor would ever fund.
Principle 12
Let the person who earned the story tell it
At the 1997 announcement, Madlyn spoke and Leonard sat in the front row. She was the cancer survivor, the Penn alumna, the trustee, and the patient of the doctor who would run the institute. Her account carried a moral authority that his, as the founder of an HMO, could not. "Having been a cancer patient, I understand the importance of a patient-centered approach." No one would have believed that line from the man who paid mothers to leave the hospital. Everyone believed it from her. The gift to Temple's dental school went further, putting the name of her father, Maurice H. Kornberg, on the building as "a wonderful present to me."
The general principle is about credibility. A message is only as credible as the messenger's connection to it. Abramson seems to have understood that his own name carried the baggage of his industry, so he let his wife's story be the public face of the giving and let the money speak for him.
Tactic: When announcing anything that matters, ask who has the most legitimate personal connection to the story, and give that person the microphone, even if it is not you.
Free playbook
Get The Business Model Playbook
58 business models, one visual page each: how the money flows, the metrics that matter, and who runs it. Free when you join the Faster Than Normal email.
Free. No spam. Unsubscribe anytime.
Part IIIQuotes and Maxims
In their words
— Leonard Abramson, to Forbes, 1991I felt I had to be successful.
— Leonard Abramson, to the New York Times, 1995When we started, the average maternity stay in a hospital was four days. Now it is 24 hours and studies show that babies are healthier, moms are healthier. The longer length of stay did not give better quality care.
— Leonard Abramson, to the Philadelphia Inquirer, 1990If industry leaders know there are solutions, they're going to call for them. Innovation leads to emulation.
— Leonard Abramson, on the 1996 sale to Aetna, to the New York TimesTo get the mass we needed, the power to negotiate with the physicians, the hospitals, the drug companies.
— Madlyn Abramson, at the announcement of the couple's $100 million gift to Penn, 1997Leonard, you made this all possible.
Maxims
- Read laws for opportunity, not just compliance. The most valuable business plan of Abramson's life was written by Congress in 1973.
- Match your corporate form to your stage. Nonprofit status absorbed the early risk and the for-profit form captured the later value, but every conversion has to be defended publicly.
- Pay for the customer's dignity, then engineer back the cost. The less efficient model that patients would accept beat the efficient one they would have refused.
- Change incentives, not rules. Paying a mother to go home early accomplished what a prohibition never could have.
- Every incentive cuts both ways. A per-patient fee that rewards keeping healthy patients healthy also penalizes treating the sick.
- Know your key number to the dollar. Two percent is $20 million, and everyone in the company should know it.
- Describe the problem so that your product is the answer. Write the indictment of your industry before someone writes it about you.
- Sell when leverage requires size you cannot reach alone. When bargaining power depends on combined scale, the founder's job becomes combining.
- Silence protects you and also leaves the story to others. If you will not explain your tradeoffs, your critics will explain them for you.
- Give with discipline and patience. Fund staged projects with an underwriter's rigor, and aim the money at the uncertain work that no one else will pay for.
